A novel in vivo gene transfer technique and in vitro cell based assays for the study of bone loss in musculoskeletal disorders

Journal of Visualized Experiments

Volumn , Issue 88, 2014, Pages

  Wu, Dennis J ^a   Dixit, Neha ^a   Suzuki, Erika ^a   Nguyen, Thanh ^b   Shin, Hyun Seock ^a   Davis, Jack ^b   Maverakis, Emanual ^c   Adamopoulos, Iannis E ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SHRINERS HOSPITALS FOR CHILDREN NORTHERN CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Arthritis; Cell culture; Hydrodynamic delivery; Issue 88; Macrophages; Medicine; Minicircle DNA; Osteoclast

Indexed keywords

EID: 84940225441     PISSN: 1940087X     EISSN: None     Source Type: Journal    
DOI: 10.3791/51810     Document Type: Article

References (35)

1. Yelin, E. Cost of musculoskeletal diseases: impact of work disability and functional decline. The Journal of rheumatology. Supplement. 68, 8-11 (2003).
2. Boyce, B. F., Rosenberg, E., de Papp, A. E., & Duong le, T. The osteoclast, bone remodelling and treatment of metabolic bone disease. European journal of clinical investigation. 42, 1332-1341, doi:10.1111/j.1365-2362.2012.02717.x (2012).
3. Lacey, D. L., et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell. 93, 165-176 (1998).
4. Mizuno, A., et al. Transgenic mice overexpressing soluble osteoclast differentiation factor (sODF) exhibit severe osteoporosis. Journal of bone and mineral metabolism. 20, 337-344, doi:10.1007/s007740200049 (2002).
5. Bucay, N., et al. osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Gene., & development. 12, 1260-1268 (1998).
6. Suda, T., & Liu, D. Hydrodynamic gene delivery: its principles and applications. Molecular therapy: the journal of the American Society of Gene Therapy. 15, 2063-2069, doi:10.1038/sj.mt.6300314 (2007).
7. Wronski, T. J., Dann, L. M., Scott, K. S., & Cintron, M. Long-term effects of ovariectomy and aging on the rat skeleton. Calcified tissue international. 45, 360-366 (1989).
8. Seto, H., Aoki, K., Kasugai, S., & Ohya, K. Trabecular bone turnover, bone marrow cell development, and gene expression of bone matrix proteins after low calcium feeding in rats. Bone. 25, 687-695 (1999).
9. Lelovas, P. P., Xanthos, T. T., Thoma, S. E., Lyritis, G. P., & Dontas, I. A. The laboratory rat as an animal model for osteoporosis research. Comparative medicine. 58, 424-430 (2008).
10. Sherman, B. M., West, J. H., & Korenman, S. G. The menopausal transition: analysis of LH, FSH, estradiol, and progesterone concentrations during menstrual cycles of older women. The Journal of clinical endocrinology and metabolism. 42, 629-636, doi:10.1210/jcem-42-4-629 (1976).
11. Hughes, D. E., et al. Estrogen promotes apoptosis of murine osteoclasts mediated by TGF-beta. Nature medicine. 2, 1132-1136 (1996).
12. Kousteni, S., et al. Nongenotropic, sex-nonspecific signaling through the estrogen or androgen receptors: dissociation from transcriptional activity. Cell. 104, 719-730 (2001).
13. Ominsky, M. S., et al. RANKL inhibition with osteoprotegerin increases bone strength by improving cortical and trabecular bone architecture in ovariectomized rats. Journal of bone and mineral research: the official journal of the American Society for Bone and Mineral Research. 23, 672-682, doi:10.1359/jbmr.080109 (2008).
14. Kitazawa, R., Kimble, R. B., Vannice, J. L., Kung, V. T., & Pacifici, R. Interleukin-1 receptor antagonist and tumor necrosis factor binding protein decrease osteoclast formation and bone resorption in ovariectomized mice. The Journal of clinical investigation. 94, 2397-2406, doi:10.1172/JCI117606 (1994).
15. Weitzmann, M. N., & Pacifici, R. Estrogen deficiency and bone loss: an inflammatory tale. The Journal of clinical investigation. 116, 1186-1194, doi:10.1172/JCI28550 (2006).
16. Suda, T., Nakamura, I., Jimi, E., & Takahashi, N. Regulation of osteoclast function. J Bone Miner Res. 12, 869-879 (1997).
17. Asagiri, M., & Takayanagi, H. The molecular understanding of osteoclast differentiation. Bone. 40, 251-264, doi:10.1016/j.bone.2006.09.023 (2007).
18. Matsuzaki, K., et al. Osteoclast differentiation factor (ODF) induces osteoclast-like cell formation in human peripheral blood mononuclear cell cultures. Biochemical and biophysical research communications. 246, 199-204, doi:10.1006/bbrc.1998.8586 (1998).
19. Adamopoulos, I. E., et al. Synovial fluid macrophages are capable of osteoclast formation and resorption. The Journal of pathology. 208, 35-43, doi:10.1002/path.1891 (2006).
20. Adamopoulos, I. E., et al. Interleukin-17A upregulates receptor activator of NF-kappaB on osteoclast precursors. Arthritis researc., & therapy. 12, R29, doi:10.1186/ar2936 (2010).
21. Jones, D., Glimcher, L. H., & Aliprantis, A. O. Osteoimmunology at the nexus of arthritis, osteoporosis, cancer, and infection. J Clin Invest. 121, 2534-2542, doi:10.1172/JCI46262 (2011).
22. Sato, K., & Takayanagi, H. Osteoclasts, rheumatoid arthritis, and osteoimmunology. Curr Opin Rheumatol. 18, 419-426, doi:10.1097/01.bor.0000231912.24740.a5 (2006).
23. Das, S., & Crockett, J. C. Osteoporosis-a current view of pharmacological prevention and treatment. Drug design, development and therapy. 7, 435-448, doi:10.2147/DDDT.S31504 (2013).
24. Chen, Z. Y., He, C. Y., Ehrhardt, A., & Kay, M. A. Minicircle DNA vectors devoid of bacterial DNA result in persistent and high-level transgene expression in vivo. Molecular therapy: the journal of the American Society of Gene Therapy. 8, 495-500 (2003).
25. Kay, M. A., He, C. Y., & Chen, Z. Y. A robust system for production of minicircle DNA vectors. Nature biotechnology. 28, 1287-1289, doi:10.1038/nbt.1708 (2010).
26. Chen, Z. Y., He, C. Y., & Kay, M. A. Improved production and purification of minicircle DNA vector free of plasmid bacterial sequences and capable of persistent transgene expression in vivo. Human gene therapy. 16, 126-131, doi:10.1089/hum.2005.16.126 (2005).
27. Halleen, J. M., et al. Tartrate-resistant acid phosphatase 5b: a novel serum marker of bone resorption. Journal of bone and mineral research: the official journal of the American Society for Bone and Mineral Research. 15, 1337-1345, doi:10.1359/jbmr.2000.15.7.1337 (2000).
28. Adamopoulos, I. E., et al. IL-23 is critical for induction of arthritis, osteoclast formation, and maintenance of bone mass. J Immunol. 187, 951-959, doi:10.4049/jimmunol.1003986 (2011).
29. Suda, T., Takahashi, N., & Martin, T. J. Modulation of osteoclast differentiation. Endocrine reviews. 13, 66-80 (1992).
30. Takahashi, N., et al. Osteoblastic cells are involved in osteoclast formation. Endocrinology. 123, 2600-2602 (1988).
31. Bradley, E. W., & Oursler, M. J. Osteoclast culture and resorption assays. Methods Mol Biol. 455, 19-35, doi:10.1007/978-1-59745-104-8_2 (2008).
32. Arai, F., et al. Commitment and differentiation of osteoclast precursor cells by the sequential expression of c-Fms and receptor activator of nuclear factor kappaB (RANK) receptors. The Journal of experimental medicine. 190, 1741-1754 (1999).
33. Fuller, K., et al. Macrophage colony-stimulating factor stimulates survival and chemotactic behavior in isolated osteoclasts. The Journal of experimental medicin. 178, 1733-1744 (1993).
34. Edwards, J. R., & Mundy, G. R. Advances in osteoclast biology: old findings and new insights from mouse models. Nature reviews. Rheumatology. 7, 235-243, doi:10.1038/nrrheum.2011.23 (2011).
35. Weinstein, R. S., et al. Promotion of osteoclast survival and antagonism of bisphosphonate-induced osteoclast apoptosis by glucocorticoids. The Journal of clinical investigation. 109, 1041-1048, doi:10.1172/JCI14538 (2002).